Moderna’s keyword for post-COVID vaccination is ‘RWE’
By Whang, byung-woo | translator Alice Kang
24.10.23 05:06:04
가나다라
0
COVID-19 hospitalization rate is still 5 times higher than the flu, underlying disease mortality 3 times higher
KDCA recommends concurrent vaccination of COVID-19 and flu vaccines...Moderna emphasizes the proven effect of its vaccines
Preannounces the introduction of a combo vaccine that can prevent influenza and COVID-19 simultaneously, domestic bridging clinical trials soon to progress
With the COVID-19 pandemic transitioning to the post-COVID-19 era, Moderna is putting forward ‘real-world evidence (RWE)’ as the keyword for its vaccines.
As the seasonal vaccination of COVID-19 vaccines has become the norm, the company has been promoting the accumulated effectiveness and safety of its vaccines.
▲(from the left) Jae-Kap Lee, Professor of Infectious Disease at Hallym University Kangnam Sacred Heart Hospital, Piyali Mukherjee, Executive Vice President, Medical Affairs, Moderna Asia Pacific
Since the pandemic, the Korea Disease Control and Prevention Agency (KDCA) has designated COVID-19 as an infectious disease that requires annual vaccination along with influenza (flu).
As a result, this year, as in previous years, the KDCA is recommending people aged 65 and older, who are at higher risk of both COVID-19 and influenza, receive both vaccines
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)